Teva Canada has issued a recall for specific Teva-Pregabalin 150 mg capsules due to potential contamination with the drug sertraline, discovered during routine testing. The affected lots are identified as 100070495 and 100068913, originally distributed in Canada starting September 2025 with an expiration date of July 31, 2027.
According to Health Canada’s recall notice, individuals sensitive or allergic to sertraline may encounter adverse effects or severe allergic reactions, such as anaphylaxis, even with minimal exposure, which could be life-threatening. Health Canada advises consumers in possession of the mentioned lots to promptly return them to a pharmacy.
Pregabalin is a medication prescribed for nerve damage-related pain management, while sertraline is used for treating depression, obsessive-compulsive disorder, and panic disorders. Teva Canada, headquartered in Toronto, describes the recall as a precautionary step in their announcement released on Friday.